EditForce
EditForce is a venture company originating from Kyushu University, utilizing proprietary RNA editing technology to create new standards in medicine, industry, and agriculture. The company aims to develop safe and innovative gene therapies targeting various diseases, including neurodegenerative, muscular, and rare diseases, by applying PPR platform technology to reduce genomic damage during treatment. Their mission is to deliver these therapies worldwide and create new value across multiple fields.
Industries
Nr. of Employees
small (1-50)
Products
Lead therapeutic program targeting myotonic dystrophy type 1 (DM1) using RNA-targeting molecules
A preclinical development program that uses sequence-specific RNA-binding molecules to bind toxic CUG-repeat DMPK mRNA and inhibit pathogenic RNA mechanisms; delivery approaches include systemic AAV vectors.
Lead therapeutic program targeting myotonic dystrophy type 1 (DM1) using RNA-targeting molecules
A preclinical development program that uses sequence-specific RNA-binding molecules to bind toxic CUG-repeat DMPK mRNA and inhibit pathogenic RNA mechanisms; delivery approaches include systemic AAV vectors.
Services
Partnership and licensing for RNA-editing platform
Collaborative development and licensing opportunities to apply the PPR-based RNA-editing platform across indications, including co-development arrangements and technology access.
Partnership and licensing for RNA-editing platform
Collaborative development and licensing opportunities to apply the PPR-based RNA-editing platform across indications, including co-development arrangements and technology access.
Expertise Areas
- RNA-targeted therapeutics development
- Gene therapy preclinical development
- RNA base editing and programmable RNA modulation
- Drug delivery system selection for nucleic-acid therapeutics (AAV, mRNA)
Key Technologies
- PPR-derived programmable RNA editing
- RNA base editing (single-nucleotide RNA substitution)
- mRNA translation activation
- Splicing modulation and exon skipping